<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Neuroscience</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D07C25C7-AC7D-4E2C-8599-6384D9A6CFA8"><gtr:id>D07C25C7-AC7D-4E2C-8599-6384D9A6CFA8</gtr:id><gtr:firstName>Brendan</gtr:firstName><gtr:surname>Payne</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800470"><gtr:id>AFA955D9-BDCA-4718-A762-CF7852CA6767</gtr:id><gtr:title>Is the treatment of HIV causing irreversible mitochondrial damage leading to long-term health consequences?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800470</gtr:grantReference><gtr:abstractText>39.5 million people are suffering from HIV/AIDS. Modern HIV treatment (HAART) has led to enormous improvements in survival, however many patients are developing disabling complications of long-term therapy such as muscle, nerve and fat damage. Once these problems develop they are usually irreversible. They are thought to arise because of damage to mitochondria (energy-producing units within our body?s cells) by certain drugs; however the mechanism is not fully understood.

We will investigate these questions by functional and genetic analyses on muscle samples from patients on various HAART regimens. We will perform functional MRI scanning, which can detect the production of energy within muscle.

We aim to show that damage to the genetic code of mitochondria is responsible for the long-term complications of certain HAART drugs, leading to a biochemical defect of mitochondrial function. We anticipate that functional MRI could detect these problems without an invasive test. These advances will help doctors choose the best therapy for patients and aid in the prevention and early detection of complications. 

The investigator is an Infectious Diseases doctor, working within the world-leading Mitochondrial Research Group at Newcastle University, providing a unique opportunity to tackle this important problem through collaborative experimental medicine and laboratory research.</gtr:abstractText><gtr:technicalSummary>Aims and Objectives: 
Highly active antiretroviral therapy (HAART) for HIV infection is associated with potentially disabling long-term complications such as myopathy, neuropathy and lipodystrophy. Mitochondrial dysfunction due to inhibition of mitochondrial DNA polymerase gamma by nucleoside reverse transcriptase inhibitors (NRTIs) is implicated in these complications, but mitochondrial DNA (mtDNA) depletion does not fully explain the pathophysiology. Our hypothesis is that accumulated somatic mtDNA mutations are more important in the long-term and irreversible complications of NRTI therapy. 

We therefore aim to: (a) determine the role of somatic mtDNA mutation in the complications of NRTI treatment; (b) assess the utility of functional MRI (fMRI) in the non-invasive investigation, and early detection of such complications.

Design and Methodology: 
(a) Muscle biopsies will be performed on the following HIV-infected subjects (n=20 per group): zidovudine-based HAART; tenofovir- or abacavir-based HAART; treatment switched to tenofovir- or abacavir-based HAART; treatment-na&amp;iuml;ve. Cryostat sections will be subjected to: COX-SDH histochemistry; single fibre laser micro-dissection; whole mitochondrial genome sequencing; mtDNA quantification by real-time PCR. Frequency of COX deficiency will be compared between treatment groups and with healthy controls, as will the spectrum of mtDNA mutations found.

(b) Zidovudine-treated and HAART-na&amp;iuml;ve subjects (n=10 each) will undergo fMRI (31P magnetic resonance spectroscopy) of lower limb muscles. Abnormal production of ATP will be correlated with clinical and histochemical findings.

Scientific and Medical Opportunities: 
We anticipate that these experiments will demonstrate that somatic mutations in mtDNA accumulate in zidovudine-treated patients. This will significantly clarify the mechanism of long-term drug complications and why they are largely irreversible. This will aid clinicians in choosing safest HAART regime. 

We anticipate that fMRI will provide a novel method for assessing mitochondrial dysfunction in antiretroviral treatment. This technique could be applied in the evaluation of new therapies, and as a diagnostic tool in patients presenting with symptoms that may be attributable to mitochondrial dysfunction. At present there is no reliable non-invasive method for evaluating such problems.

This work is clinically important because an enormous number of people are infected with HIV worldwide. Zidovudine continues to be a key drug, particularly in the developing world, where it is first-choice agent. Furthermore as somatic mtDNA mutations take time to accumulate, and antiretroviral therapy has only been widely available for a relatively short period of time it is important to know whether there is a ticking ?time-bomb? of secondary mtDNA disease.</gtr:technicalSummary><gtr:fund><gtr:end>2011-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>195163</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media coverage of publication</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3AD5D39D-BED5-4F84-8177-FB1CB7FCF075</gtr:id><gtr:impact>Press release of paper was picked up by multiple general and specialist media sources, including Daily Mail and Reuters websites.

Unknown</gtr:impact><gtr:outcomeId>oKh4xqMgbBm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Co-funded PhD studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>A44BAA3B-0C55-4037-87DB-5AFBBAA4E448</gtr:id><gtr:outcomeId>VRrr7o3dy220</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>BRC for Ageing - Incubator Grant</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>096D5EA3-331B-4C36-8D27-9D8A35710CE5</gtr:id><gtr:outcomeId>F11C973EA3E0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Established a research tissue bank for control muscle tissue ('Mitochondrial Control Tissue Bank', MCTB), to act as comparator group for this study and other future work.</gtr:description><gtr:id>49C4CDB9-3BA4-4410-B02F-ABC0D26B691F</gtr:id><gtr:impact>Contributed to the Nature Genetics paper (see above)</gtr:impact><gtr:outcomeId>C8vMZryeWfv</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MCTB</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F0862C20-F0D2-4E05-A8BD-C2FF1339AFBE</gtr:id><gtr:title>In vivo mitochondrial function in HIV-infected persons treated with contemporary anti-retroviral therapy: a magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54510de87241f8.95051607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF42507E-B2C8-41AA-9E8A-FE9898B23EB9</gtr:id><gtr:title>In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21120c5a83ffe6b0704e78412e17c3e8"><gtr:id>21120c5a83ffe6b0704e78412e17c3e8</gtr:id><gtr:otherNames>Bulst S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>pm_12521_21_22608879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B16F9357-1FC3-4EC9-A38D-A14AB671A955</gtr:id><gtr:title>HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms?</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_12521_21_22998022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8F93906-A373-4C6A-BFCE-A37927A871BA</gtr:id><gtr:title>Age-related mitochondrial DNA depletion and the impact on pancreatic Beta cell function.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2caf1008353fc4c0d685961ad9d30d8d"><gtr:id>2caf1008353fc4c0d685961ad9d30d8d</gtr:id><gtr:otherNames>Nile DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56dbfda959c648.87725214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>189DACED-B8C1-43C8-B81F-4440B1E9F84D</gtr:id><gtr:title>HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies.</gtr:title><gtr:parentPublicationTitle>Toxicologic pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da7de470552fbe19eaeccb55dde6bf0e"><gtr:id>da7de470552fbe19eaeccb55dde6bf0e</gtr:id><gtr:otherNames>Gardner K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0192-6233</gtr:issn><gtr:outcomeId>54510de804cb77.90909693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98EDFC62-1EDD-47CD-9E7C-9D273A447A6D</gtr:id><gtr:title>Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc711ae725d40651b72d79a494177f81"><gtr:id>dc711ae725d40651b72d79a494177f81</gtr:id><gtr:otherNames>Samuels R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a992b4a2e4758.10874436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B28D6CD0-26D1-485E-969D-D585F8FB953C</gtr:id><gtr:title>Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>hyjbXzw2kqr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63EB75B6-66C1-4A72-A2A5-686D2C4760AA</gtr:id><gtr:title>Deep resequencing of mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56dbfcdeb63ac0.88710911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB5B72C4-AA91-4098-A351-AA8F7B973908</gtr:id><gtr:title>The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8bb9524a998e77f17813674e4a71825"><gtr:id>b8bb9524a998e77f17813674e4a71825</gtr:id><gtr:otherNames>Widdrington J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>54510de7338417.54621259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B96536FF-4812-4D8D-A266-40DC86D94CA4</gtr:id><gtr:title>Hepatitis E virus seroprevalence among men who have sex with men, United Kingdom.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>54510de7997f97.07252125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18ACF9C1-1C4B-45E1-9256-A5B3013F2C98</gtr:id><gtr:title>Mitochondrial DNA mutations in ageing and disease: implications for HIV?</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>54510de9eb17e4.10598584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C327FC6A-D22F-45DF-BC88-94F59F45A420</gtr:id><gtr:title>Segregation of mitochondrial DNA heteroplasmy through a developmental genetic bottleneck in human embryos.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbfaff3746d076dc880da936c7770bb3"><gtr:id>cbfaff3746d076dc880da936c7770bb3</gtr:id><gtr:otherNames>Floros VI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>5a992b2ac7b937.73599581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B477DFE5-D21D-4993-931A-B356DE84C0EB</gtr:id><gtr:title>Mitochondrial dysfunction in aging: Much progress but many unresolved questions.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56dbfb8ca608e6.03800126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2E35F05-DD6F-4B13-8800-6C27F7F0DB22</gtr:id><gtr:title>Unique mitochondrial DNA in highly inbred feral cattle.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65eb931f142b9d0a96c1e2e4b5b1f6a7"><gtr:id>65eb931f142b9d0a96c1e2e4b5b1f6a7</gtr:id><gtr:otherNames>Hudson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn><gtr:outcomeId>pm_12521_21_22609322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF48E442-5A69-4A0E-8AB1-96D9301662CD</gtr:id><gtr:title>Universal heteroplasmy of human mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12521_21_23077218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>813E1386-32C4-4EFB-977F-FBA4FF4A120B</gtr:id><gtr:title>Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e8b394438d706d8ec79a1881109468"><gtr:id>b8e8b394438d706d8ec79a1881109468</gtr:id><gtr:otherNames>Pfeffer G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>54510de90b3380.47146074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD850197-F18F-4EBA-96F2-E1340B40AD9C</gtr:id><gtr:title>Understanding the Implications of Mitochondrial DNA Variation in the Health of Black Southern African Populations: The 2014 Workshop.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6642f67c035f6540234de88b998dff7"><gtr:id>c6642f67c035f6540234de88b998dff7</gtr:id><gtr:otherNames>van der Westhuizen FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>56dbfb8d1f7a23.14302252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65F20CF3-865E-4BEE-9EFF-ED997707F6BC</gtr:id><gtr:title>Severe toxicity and polymerase-? gene abnormalities in Malawian adults on stavudine-based antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf045c357cab93673df461672ada7234"><gtr:id>cf045c357cab93673df461672ada7234</gtr:id><gtr:otherNames>van Oosterhout JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>54510de7c6fa43.80479322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>155928FF-3A3B-4D3D-970B-90C888DCF815</gtr:id><gtr:title>Single-cell analysis of mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56dbfcde94f884.99253800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>771BC913-4421-40FA-A685-46445D8A928B</gtr:id><gtr:title>Orthostatic intolerance is common in chronic disease--a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afa82016345f415704bcfe5850a2f651"><gtr:id>afa82016345f415704bcfe5850a2f651</gtr:id><gtr:otherNames>Frith J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn><gtr:outcomeId>54510de94aff73.88580829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DC205DB-36CB-4F62-B395-D5B492CEE551</gtr:id><gtr:title>Molecular pathogenesis of polymerase ?-related neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ad31ee1a86f6ba14e92eb598b85fe9e"><gtr:id>3ad31ee1a86f6ba14e92eb598b85fe9e</gtr:id><gtr:otherNames>Tzoulis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>54510de98c1d31.36549548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C42312F3-0C0B-4DC9-A371-7775A3ACD2AF</gtr:id><gtr:title>Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d5d618d31b1d170b90a2083007ae6c"><gtr:id>45d5d618d31b1d170b90a2083007ae6c</gtr:id><gtr:otherNames>Payne BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>54510de83b16e5.27904215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64F8B645-D051-4DA1-8B06-7803F4F723BD</gtr:id><gtr:title>Use of stereotypical mutational motifs to define resolution limits for the ultra-deep resequencing of mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da7de470552fbe19eaeccb55dde6bf0e"><gtr:id>da7de470552fbe19eaeccb55dde6bf0e</gtr:id><gtr:otherNames>Gardner K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>54510de9bc8652.83070653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47312BEF-B3D6-40BC-9550-A4BF53D88F77</gtr:id><gtr:title>Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/259bacbf5a696ae04385c90a10e4ab61"><gtr:id>259bacbf5a696ae04385c90a10e4ab61</gtr:id><gtr:otherNames>Gorman GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56dbfb8cd4bb10.27686108</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800470</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>